Working... Menu

Neoadjuvant Atezolizumab in Localized Bladder Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02451423
Recruitment Status : Recruiting
First Posted : May 22, 2015
Last Update Posted : April 5, 2019
Information provided by (Responsible Party):
Lawrence Fong, University of California, San Francisco

Brief Summary:

This is a single arm, open label Phase II study of MPDL3280A, an anti-PD-L1 antibody administered as neoadjuvant therapy to subjects with either BCG-refractory non-muscle invasive transitional cell carcinoma (TCC) of the bladder, or muscle-invasive TCC appropriate for cystectomy and refusing or ineligible for neoadjuvant chemotherapy. Enrolled patients will be assigned sequentially to dose levels in cohorts of 6 patients per dose level. The starting dose level is 1200mg x 1 dose and will be escalated in subsequent cohorts to 1200mg q 3 weeks x 2 doses, and finally 1200mg q 3 weeks x 3 doses to determine the impact of increasing number of treatments on the modulated immune response with the tumor tissue. Subjects with adverse pathology (pT3/pT4 or N+) will be offered the option of adjuvant MPDL3280A for up to 16 cumulative cycles of treatment.

After all neoadjuvant study therapy is administered, each subject will undergo cystectomy to evaluate pathologic response to treatment and for immunologic characterization in the resected tissue. Serum and urine will be obtained as well to characterize circulating immune responses. After the multi-dose portion of the study has completed accrual two expansion cohorts of up to 15 patients each with NMIBC or MIBC will be accrued at the highest dose level for further characterization of safety, efficacy, and immunologic analysis. Patients with pT3, pT4, or N+ disease at the time of cystectomy and no metastatic disease will be offered the option of adjuvant MPDL3280A for up to a total of 16 cumulative cycles. All subjects will be followed clinically for up to 2 years to assess for disease recurrence.

Condition or disease Intervention/treatment Phase
Carcinoma, Transitional Cell Drug: MPDL3280A Dose Level 1 Drug: MPDL3280A Dose Level 2 Drug: MPDL3280A Dose Level 3 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects With Non-metastatic Transitional Cell Carcinoma of the Bladder
Study Start Date : April 2016
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: MPDL3280A
MPDL3280A: Intravenously; Day 1 of each 21-day Cycle
Drug: MPDL3280A Dose Level 1
1200 mg x 1 dose

Drug: MPDL3280A Dose Level 2
1200 mg every 3 weeks x 2 doses

Drug: MPDL3280A Dose Level 3
1200 mg evert 3 weeks x 3 doses

Primary Outcome Measures :
  1. Change in CD3+ T cell count/µm2 [ Time Frame: Up to 1 year ]
  2. Pathologic T0 rate [ Time Frame: procedure ]
    Pathologic absence of disease in the bladder

Secondary Outcome Measures :
  1. Adverse Events [ Time Frame: Up to 2 years ]
  2. Percentage of treatment-related delay in surgery [ Time Frame: Starting at Week 12 ]
  3. Frequency of treatment related Adverse Events [ Time Frame: Up to 6 months ]
  4. Frequency of treatment related Adverse Events [ Time Frame: Up to 2 years ]
    Adjuvant MPDL3280A therapy given every 3 weeks for up to 16 cumulative cycles (including neoadjuvant therapy) will be offered as optional therapy for subjects with adverse pathology (pT3/pT4, or N+) at the time of surgery.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • ECOG performance status 0, 1
  • Histologically document transitional cell carcinoma with the presence of any of the following stages: CIS, high-grade Ta, any grade T1, or any grade cT2-T4, considered appropriate for radical cystectomy. Subjects with mixed histology are required to have a dominant TCC pattern.
  • For subjects with NMIBC, BCG-refractory or BCG-resistant disease. BCG-refractory disease is defined as the absence of a complete response by 6 months in patients who have received induction and maintenance OR two induction courses of BCG. BCG-resistant disease is defined as persistent or recurrent disease after 2 induction courses of BCG within 1 year OR cancer recurrence within 1 year of initiation of therapy for patients who have received induction plus maintenance BCG therapy. Subjects with NMIBC must be suitable for and willing to undergo a radical cystectomy at the completion of study therapy.
  • For subjects with muscle invasive disease: not suitable neoadjuvant cisplatin-based chemotherapy as determined by the following:
  • Creatinine clearance less than 60ml/min. GFR should be assessed by calculation from serum/plasma creatinine (Cockcroft-Gault formula)
  • CTCAE Gr >/= 2 hearing loss
  • CTCAE Gr >/= 2 neuropathy
  • Subjects with MIBC not meeting the above criteria are still eligible provided the patient declines neoadjuvant cisplatin-based chemotherapy, after specific informed consent describing the known benefits of cisplatin-based chemotherapy. The reason for declining must be documented.
  • Adequate bone marrow function defined as
  • WBC > 2500 cells/mm3
  • ANC > 1500 cells/mm3
  • Hemoglobin > 9 g/dL. Patients may be transfused or receive erythropoietic treatment to meet this criterion.
  • Platelet count > 100,000 cells/mm3
  • Adequate renal function: Serum creatinine < 2 mg/dL OR calculated CrCl > 30ml/min
  • Serum bilirubin < 1.5 x ULN (except for patients with documented Gilbert's disease)
  • AST and ALT < 2.5 x ULN
  • Ability to understand and willingness to sign a written informed consent.
  • Have available evaluable archival tumor tissue for PD-L1 biomarker assessment. Presence of PD-L1 antigen on tumors is NOT required for study entry.
  • The effects of MPDL3280A on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception prior to study entry, during study participation, and for 90 days after study treatment discontinuation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 90 days after completion of study drug administration.

Exclusion Criteria:

  • Subjects with primary TCC of the ureter, urethra, or renal pelvis without TCC of the bladder are not allowed.
  • Known distant metastatic disease (e.g. pulmonary or hepatic metastases).
  • Subjects with malignant lymphadenectomy in the abdomen or pelvis considered appropriate for radical cystectomy and lymphadnectomy with the goal of complete resection of all malignant disease are allowed.
  • Intravesical chemo- or biologic therapy within 6 weeks of first treatment.
  • Prior systemic chemotherapy or radiation therapy for transitional cell carcinoma of the bladder.
  • Subjects who have received prior intravesical chemotherapy are allowed.
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti CTLA-4, anti-PD1 and anti-PD-L1 therapeutic antibodies.
  • History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegner's granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, multiple sclerosis, vacuities, or glomerulonephritis.
  • Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone are eligible for this study.
  • Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen are eligible for this study.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
  • History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • Chronic liver disease
  • HIV or active hepatitis B virus (HBV; chronic or acute; defined as having a positive hepatitis B surface antigen [Bag] test at screening) or active hepatitis C
  • Patients with past HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBc Ab] and absence of HBsAg) are eligible. HBV DNA must be obtained in these patients prior to Cycle 1, Day 1, but detection of HBV DNA in these patients will not exclude study participation.
  • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  • Active tuberculosis
  • Severe infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
  • Prior allogeneic stem cell or solid organ transplant
  • Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study. Inactivated vaccines (such as hepatitis A or polio vaccines) are permitted during the study.
  • Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to Cycle 1, Day 1 and for at least 12 weeks after the last dose.
  • Clinically significant active infection or uncontrolled medical condition
  • Uncontrolled cystitis, significant bladder pain or spasms, or gross hematuria that in the opinion of the treating investigator, should preclude study entry.
  • Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina
  • Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction < 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate.
  • Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure other than cystectomy during the course of the study
  • Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1, or anticipated requirement for systemic immunosuppressive medications during the trial
  • Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study after discussion with and approval by the Study Chair.
  • The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone for adrenal insufficiency) is allowed.
  • Pregnant or nursing women are excluded
  • Known hypersensitivity to Chinese hamster ovary (CHO) cell products or any component of the MPDL3280A formulation
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Malignancies other than UC within 5 years prior to Cycle 1, Day 1, with the exception of those with a low risk of metastasis or death treated with expected curative outcome (such as, but not limited to, adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent and absence of PSA relapse, or ductal carcinoma in situ of the breast treated surgically with curative intent) or incidental prostate cancer (T1a, Gleason score ≤ 6 and PSA < 0.5 ng/mL).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02451423

Layout table for location contacts
Contact: Lawrence Fong, MD 877-827-3222

Layout table for location information
United States, California
University of California, San Francisco Recruiting
San Francisco, California, United States, 94158
Contact: Lawrence Fong, MD    877-827-3222   
Sponsors and Collaborators
University of California, San Francisco
Layout table for investigator information
Principal Investigator: Lawrence Fong, MD University of California, San Francisco

Layout table for additonal information
Responsible Party: Lawrence Fong, Professor in Residence, University of California, San Francisco Identifier: NCT02451423     History of Changes
Other Study ID Numbers: 14524
First Posted: May 22, 2015    Key Record Dates
Last Update Posted: April 5, 2019
Last Verified: April 2019

Keywords provided by Lawrence Fong, University of California, San Francisco:

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs